专利检索 ap:("THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES") AND inv:"Oluyomi M. Okunola-Bakare" 第 1 页

1.

发明授权
Potent and selective inhibitors of monoamine transporters; method of making; and use thereof 有权

公开(公告)号：US10590074B2

公开(公告)日：2020-03-17

申请号：US15830244

申请日：2017-12-04

申请人： THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health

发明人： Amy Hauck Newman , Oluyomi M. Okunola-Bakare , Jianjing Cao

IPC分类号： C07C323/60 , A61K45/06 , A61K31/135 , C07C317/44 , C07C317/28 , C07C323/25 , C07D295/08 , C07D295/088 , C07D295/108 , C07D295/185

摘要： Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (DA), serotonin (5-HT), and/or norepinephrine (NE) reuptake via their respective transporters, DAT, SERT and NET. Also disclosed are methods for eliciting a wake-promoting or cognitive or attention enhancing effect and for treating substance use disorders, attention deficit (hyperactivity) disorder, depressive disorders, bipolar disorder or other neuropsychiatric disorders sleep disorders or cognitive impairment using the compounds.

2.

发明授权
Potent and selective inhibitors of monoamine transporters; method of making; and use thereof 有权

公开(公告)号：US11555013B2

公开(公告)日：2023-01-17

申请号：US17139583

申请日：2020-12-31

申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： Amy Hauck Newman , Oluyomi M. Okunola-Bakare , Jianjing Cao

IPC分类号： A61K45/06 , C07C323/60 , A61K31/135 , C07C317/44 , C07C317/28 , C07C323/25 , C07D295/08 , C07D295/088 , C07D295/108 , C07D295/185

摘要： Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (DA), serotonin (5-HT), and/or norepinephrine (NE) reuptake via their respective transporters, DAT, SERT and NET. Also disclosed are methods for eliciting a wake-promoting or cognitive or attention enhancing effect and for treating substance use disorders, attention deficit (hyperactivity) disorder, depressive disorders, bipolar disorder or other neuropsychiatric disorders sleep disorders or cognitive impairment using the compounds.